Press Releases.

Month Year

Month Year

Investor Alerts

September 20, 2023

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
September 13, 2023

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
September 05, 2023

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
August 23, 2023

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
August 08, 2023

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
August 02, 2023

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
July 18, 2023

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
June 27, 2023

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 23, 2023

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
June 20, 2023

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Show per page